Pharmacogenomic study in patients with multiple sclerosis Responders and nonresponders to IFN-&#946; by M.F. Bustamante et al.
Marta F. Bustamante,
PhD
Carlos Morcillo-Suárez,
PhD
Sunny Malhotra, PhD
Jordi Rio, MD
Laura Leyva, PhD
Oscar Fernández, MD
Uwe K. Zettl, MD
Joep Killestein, MD
David Brassat, MD
Juan Antonio García-
Merino, MD
Antonio J. Sánchez, PhD
Elena Urcelay, PhD
Roberto Alvarez-Lafuente,
PhD
Lusia M. Villar, MD
Jose Carlos Alvarez-
Cermeño, MD
Xavier Farré, PhD
Jeannette Lechner-Scott,
MD
Koen Vandenbroeck,
PhD
Alfredo Rodríguez-
Antigüedad, MD
Jelena S. Drulovic, MD
Filippo Martinelli
Boneschi, MD
Andrew Chan, MD
Jorge Oksenberg, PhD
Arcadi Navarro, PhD
Xavier Montalban, MD
Manuel Comabella, MD
Correspondence to
Dr. Comabella:
manuel.comabella@vhir.org
Supplemental data
at Neurology.org/nn
Pharmacogenomic study in patients with
multiple sclerosis
Responders and nonresponders to IFN-b
ABSTRACT
Objectives:Weaimed to investigate the association between polymorphisms located in type I interferon
(IFN)-induced genes, genes belonging to the toll-like receptor (TLR) pathway, and genes encoding neu-
rotransmitter receptors and the response to IFN-b treatment in patients with multiple sclerosis (MS).
Methods: In a first or screening phase of the study, 384 polymorphisms were genotyped in 830
patients with MS classified into IFN-b responders (n5 416) and nonresponders (n5 414) accord-
ing to clinical criteria. In a second or validation phase, the most significant polymorphisms asso-
ciated with IFN-b response were genotyped in an independent validation cohort of 555 patients
with MS (281 IFN-b responders and 274 nonresponders).
Results: Seven single nucleotide polymorphisms (SNPs) were selected from the screening phase for
further validation: rs832032 (GABRR3; p 5 0.0006), rs6597 (STUB1; p 5 0.019), rs3747517
(IFIH1; p5 0.010), rs2277302 (PELI3; p5 0.017), rs10958713 (IKBKB; p5 0.003), rs2834202
(IFNAR1; p5 0.030), and rs4422395 (CXCL1; p5 0.017). None of these SNPs were significantly
associated with IFN-b response when genotyped in an independent cohort of patients. Combined
analysis of these SNPs in all patients with MS (N 5 1,385) revealed 2 polymorphisms associated
with IFN-b response: rs2277302 (PELI3; p 5 0.008) and rs832032 (GABRR3; p 5 0.006).
Conclusions: These findings do not support an association between polymorphisms located in genes
related to the type I IFN or TLR pathways or genes encoding neurotransmitter receptors and the clinical
response to IFN-b. Nevertheless, additional genetic and functional studies of PELI3 and GABRR3 are
warranted. Neurol Neuroimmunol Neuroinflamm 2015;2:e154; doi: 10.1212/NXI.0000000000000154
GLOSSARY
EDSS 5 Expanded Disability Status Scale; GABA 5 g-aminobutyric acid; IFN 5 interferon; MS 5 multiple sclerosis; SNP 5
single nucleotide polymorphism; TLR 5 toll-like receptor.
Interferon b (IFN-b) is one of the most widely prescribed disease-modifying therapies for
patients with relapsing-remitting multiple sclerosis (MS) and has demonstrated positive
effects on reducing disease activity.1 However, IFN-b is only partially effective, and a
significant proportion of patients with MS do not respond to this treatment.2 Despite
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many efforts to identify allelic variants
influencing the response to IFN-b,3 to date
there is a lack of genetic biomarkers reliably
associated with therapeutic response.
A previous IFN-b transcriptomic study
conducted by our group (Cemcat) implicated
genes belonging to the type I IFN pathway
and genes related to the toll-like receptor
(TLR) pathway in the clinical response to
IFN-b.4 The 2 genome-wide pharmacoge-
nomic studies published thus far in relation
to the response to IFN-b5,6 reported the
involvement of type I IFN– responsive genes5
and the overrepresentation of genes coding
for glutamate and g-aminobutyric acid (GA-
BA) receptors among the polymorphisms that
best discriminated between IFN-b respond-
ers and nonresponders, suggesting a relation-
ship between neuronal excitation and response
to IFN-b.5,6
Building on these observations, in the pre-
sent study we aimed to genotype an extensive
panel of polymorphisms located in genes related
to the type I IFN and TLR pathways and genes
coding for GABA and glutamate receptors in a
multicenter cohort of IFN-b responders and
nonresponders in order to investigate their
potential association with the response to this
treatment.
METHODS Definition of response to IFN-b therapy.
Patients with relapse-onset MS treated with IFN-b and with
a follow-up of at least 2 years were classified as responders and
nonresponders. Responders were patients with no relapses and
no increase in the Expanded Disability Status Scale (EDSS)
score over the follow-up period. Nonresponders were patients
having 1 or more relapses during the follow-up period and an
increase in the EDSS score of at least 1 point confirmed at 6
months.7 We further classified the response of a subgroup of
patients according to the number of relapses during the first 2
years of treatment without considering EDSS progression.
Responders had no relapses during the follow-up period. Two
different criteria were considered for nonresponders: (1) 1 or
more relapses during the 2-year follow-up (criteria 1), and (2) 2
or more relapses over the follow-up period (for this criterion,
patients with only 1 relapse were not considered in the analysis;
criteria 2).
Information on the IFN-b neutralizing antibody status was
not available for patients included in the study.
Single nucleotide polymorphism selection. Genes related
to the type I IFN and TLR pathways and genes coding
for GABA and glutamate receptors were selected through
bibliographical searches, and a total of 384 biologically
informative single nucleotide polymorphisms (SNPs)
were selected for genotyping using Select Your SNPs, an
online tool for selecting tagSNPs from a roster of candidate
genes.8
Study design. In a first or screening phase of the study (phase I),
384 SNPs were genotyped in 830 patients withMS classified accord-
ing to their response to IFN-b. There were 416 responders and 414
nonresponders. Genomic DNA samples were obtained using stan-
dard methods and genotyping was performed using an Illumina
GoldenGate assay at Progenika Biopharma SA (Bizkaia, Spain).
Overall genotyping success rate was 95%. The full list of
SNPs and probes is provided as table e-1 at Neurology.org/nn.
In a second or validation phase of the study (phase II), the
most significant SNPs obtained in phase I were genotyped in
an independent cohort of 555 patients with MS (281 responders
and 274 nonresponders to IFN-b). Genotyping was performed
using TaqMan assays at the Cemcat (Barcelona, Spain). Geno-
typing success rate was 97%.
A summary of demographic and baseline clinical characteris-
tics of all patient cohorts is shown in table 1.
Statistical analysis. Data processing, missingness, Hardy-
Weinberg analysis, and allele frequency comparisons between
responders and nonresponders to IFN-b were performed with
SNPator (www.snpator.org).9 Possible stratification owing to
different population origin was assessed using the Cochran-
Mantel-Haenszel test implemented in PLINK (http://pngu.
mgh.harvard.edu/;purcell/plink/).
Standard protocol approvals, registrations, and patient
consents. The study was approved by the corresponding local
ethics committee, and all patients gave their informed consent.
RESULTS In the first phase of the study, a total of 384
SNPs were genotyped in 830 patients withMS classified
according to their clinical response to IFN-b treatment.
The results of the allelic association analysis for all the
study cohorts (combined and stratified by MS center)
are shown in table e-2. The most significant SNPs asso-
ciated with the response to IFNb were selected for fur-
ther validation (table 2): (1) rs832032 (GABRR3; p 5
0.0006), (2) rs6597 (STUB1; p 5 0.019), (3)
rs3747517 (IFIH1; p5 0.010), (4) rs2277302 (PELI3;
p 5 0.017), (5) rs10958713 (IKBKB; p 5 0.003), (6)
rs2834202 (IFNAR1; p 5 0.030), and (7) rs4422395
(CXCL1; p 5 0.017).
In a second phase of the study, these 7 SNPs were
genotyped in an independent cohort of 555 patients
with MS classified according to the same clinical cri-
teria as in phase I. As depicted in table 2, allelic anal-
ysis in this validation cohort showed a lack of
statistically significant associations between selected
polymorphisms from phase I and the response to
IFN-b (figure e-1). Combined analysis in the whole
cohort of patients with MS (N 5 1,385; table 2)
revealed 2 SNPs associated with the response to
IFN-b with p values below 0.01: rs2277302, a syn-
onymous polymorphism located in the PELI3 gene;
and rs832032, a polymorphism located in the
GABRR3 gene that results in a premature stop codon
and protein truncation.
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Table 1 Summary of demographic and baseline clinical characteristics for all the cohorts of patients with MS (responders and nonresponders to IFN-b treatment)
Phase Sets
N Female/male (% female) Age, y Disease duration, y EDSS IFN-b (1/2/3)a
R NR R NR R NR R NR R NR R NR
I Toulouse 67 68 53/14 (80.1) 47/21 (69.1) 28.9 (8.0) 27.9 (8.7) 4.5 (5.4) 4.8 (5.8) 2.0 (1.2) 1.7 (1.3) 15/39/13 16/36/16
Serbia 24 24 17/7 (70.8) 15/9 (62.5) 31.9 (6.4) 33.3 (7.8) 3.6 (3.5) 6.1 (4.9) 0.9 (0.8) 2.3 (0.9) 12/0/12 14/0/10
Bochum 4 4 2/2 (50.0) 2/2 (50.0) 37.8 (4.6) 36.0 (9.8) 3.8 (3.8) 4.3 (3.6) 2.1 (1.1) 3.9 (2.5) 0/1/3 1/1/2
Rostock 43 43 36/7 (83.7) 36/7 (83.7) 40.9 (9.9) 38.3 (11.4) 5.0 (4.8) 4.6 (5.8) 1.8 (1.6) 3.0 (1.7) 12/9/22 6/6/31
Newcastle 32 32 25/7 (78.1) 25/7 (78.1) 42.0 (11.1) 35.2 (12.2) 6.3 (9.1) 6.0 (5.6) — — 16/2/14 16/2/14
San Francisco 2 2 2/0 (100) 2/0 (100) 40.5 (6.4) 41.5 (6.4) 1.9 (0.9) 3.7 (4.1) 1.0 (1.4) 1.5 (0.7) 1/1/0 1/1/0
Milan 6 6 4/2 (66.7) 3/3 (50.0) 39.6 (8.8) 40.8 (15.8) 3.7 (5.1) 6.3 (7.2) 1.5 (0.8) 2.5 (1.8) 4/2/0 4/2/0
Madrid PH 20 20 12/8 (60.0) 14/6 (70.0) 37.7 (8.3) 32.7 (9.8) 4.6 (2.7) 7.2 (2.8) — — 10/5/5 10/8/2
Madrid SC 29 30 21/8 (72.4) 15/15 (50.0) 33.4 (7.4) 34.1 (7.7) 5.3 (4.8) 5.1 (6.5) 2.0 (1.6) 2.1 (1.3) 12/7/10 12/5/13
Malaga 32 32 23/9 (71.9) 23/9 (71.9) 40.0 (9.5) 44.0 (10.8) 16.0 (4.0) 15.0 (7.6) 1.0 (1.3) 2.0 (1.4) 10/17/5 9/16/7
Bilbao 28 25 21/7 (75.0) 18/7 (72.0) 36.5 (9.8) 34.0 (8.4) 8.0 (7.4) 8.1 (8.2) 2.2 (2.0) 2.5 (1.5) 13/3/12 11/5/9
Barcelona 129 128 103/26 (79.8) 99/29 (77.3) 40.8 (8.8) 40.9 (10.3) 13.7 (7.2) 13.3 (7.3) 2.4 (1.8) 5.3 (2.1) 38/37/54 34/36/58
All phase I 416 414 319/97 (76.7) 299/115 (72.2) 37.5 (4.1) 36.5 (4.6) 6.4 (7.0) 7.0 (3.5) 1.7 (0.5) 2.7 (1.1) 143/123/150 134/118/162
II Madrid RC 33 41 27/6 (81.8) 29/12 (70.7) 38.0 (9.4) 35.9 (9.2) 6.2 (6.1) 3.8 (5.2) 1.6 (0.8) 1.8 (1.3) 21/4/8 22/13/6
Malaga 129 114 82/47 (63.6) 75/39 (65.8) 45.5 (11.1) 46.8 (11.1) 16.3 (7.9) 17.3 (7.6) 1.4 (1.5) 1.7 (1.4) 48/27/48 41/38/3
Rostock 43 43 36/7 (83.7) 36/7 (83.7) 37.7 (10.2) 35.5 (11.1) 3.0 (0.9) 3.1 (0.9) 1.8 (1.3) 2.2 (1.1) 9/17/17 6/7/30
Amsterdam 76 76 55/21 (72.3) 50/24 (67.6) 35.5 (8.3) 35.0 (9.4) 4.0 (4.2) 4.2 (4.0) 2.5 (1.3) 3.1 (1.4) 24/27/25 18/25/31
All phase II 281 274 200/81 (71.2) 190/84 (6.9) 40.6 (11.0) 40.14 (11.8) 9.8 (8.7) 9.9 (8.8) 1.8 (1.4) 2.2 (1.5) 102/75/98 87/83/70
Both phases All cohorts 698 688 519/178 (74.5) 489/199 (71.1) 38.6 (10.6) 37.7 (11.6) 8.9 (8.0) 8.7 (7.9) 1.8 (1.5) 2.7 (2.1) 245/198/248 221/201/232
Abbreviations: EDSS 5 Expanded Disability Status Scale; IFN 5 interferon; Madrid PH 5 Hospital Universitario Puerta de Hierro, Madrid; Madrid RC 5 Hospital Ramón y Cajal, Madrid; Madrid SC 5 Hospital Clínico
San Carlos; NR 5 nonresponder; R 5 responder.
Unless otherwise indicated, data are expressed as mean (SD).
a IFN-b (1a intramuscular/1b subcutaneous/1a subcutaneous).
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A classification of the response to IFN-b based
only on the number of relapses during the first 2 years
of treatment was performed in a subgroup of 526
patients with MS from the screening cohort. It did
not result in stronger associations with the response to
IFN-b relative to the combined classification includ-
ing relapses and EDSS progression (table e-3 for cri-
teria 1; table e-4 for criteria 2).
DISCUSSION Previous pharmacogenomic studies
have suggested a role for genes responsive to type I
IFNs, genes related to the TLR pathway, and genes
coding for neurotransmitter receptors in the response
to IFN-b treatment in patients with MS.4–6 Promp-
ted by these observations, we genotyped an extensive
panel of polymorphisms positioned in genes within
these pathways in a large multicenter cohort—the
largest thus far published in the field—of responders
and nonresponders to IFN-b. Classification of pa-
tients with MS into IFN-b responders and nonres-
ponders was conducted after 2 years of follow-up
according to common stringent criteria based on
the presence of relapses and progression of the
EDSS score. These clinical criteria were similar to
those used in previous studies.4–6
Despite the statistically significant associations
with the response to IFN-b observed for some of
the SNPs genotyped in the screening phase of the
study, none of these associations remained signifi-
cant following genotyping in an independent cohort
of responders and nonresponders to IFN-b. While
the reasons for this lack of association observed
between selected polymorphisms from the screening
phase and the response to IFN-b are manifold, a lack
of statistical power to detect statistically significant
associations in the validation cohort cannot totally
be ruled out. In fact, combined analysis in the whole
cohort of 1,385 patients with MS revealed signifi-
cant associations for 2 polymorphisms, rs832032
and rs2277302.
Rs832032 is located in the GABRR3 gene and enc-
odes a subunit of the GABA(C) receptor. It is inter-
esting that this polymorphism results in a premature
stop codon and subsequent protein truncation. At pre-
sent, there is no evidence in the literature of a func-
tional relationship between GABA(C) receptors and
IFN-b mechanism of action.
Rs2277302 is a synonymous SNP located in the
PELI3 gene, which codes for an E3 ubiquitin protein
ligase involved in TLR signaling. In a recent publica-
tion,10 Peli3-deficient mice expressed increased levels
of endogenous IFN-b in response to TLR3 activa-
tion, and an autoregulation mechanism was proposed
in which PELI3 inhibited type I IFNs by targeting
IFN regulatory factor 7. These findings are in agree-
ment with previous data from our group revealing
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increased baseline levels of endogenous IFN-b in
peripheral blood cells from IFN-b nonresponders.11
Overall, results from this study do not support an
association between polymorphisms positioned in
genes belonging to the type I IFN or TLR pathways
or genes coding for GABA or glutamate receptors and
the clinical response to IFN-b. Findings with
rs832032 and rs2277302 polymorphisms warrant
further studies exploring the role of GABRR3 and
PELI3 in the response to IFN-b in larger cohorts of
patients with MS.
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